Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.

NCT00301457 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.

NCT NCT00301457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00301457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.
Lead sponsor
Maastricht University Medical Center
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
April 30, 2022
Enrollment
1,914 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer